Literature DB >> 176379

Genetic analysis of mammary tumor induction and expression of mammary tumor virus antigen in hormone-treated ovariectomized GR mice.

R van Nie, J Hilgers.   

Abstract

Early stages of mammary tumors (EMT) were induced with a combined treatment of progesterone (P) and estrone (E) in ovariectomized adult GRS/A (GR) mice, a strain of European origin and with a high incidence of mammary cancer. The mammary tumors were comparable to the pregnancy-dependent tumors of breeding females of this strain. The hormone treatment did not lead to EMT in a variety of other strains and only occasionally in the RIII an C3H strains. Treatment with P or E alone di not lead to EMT in GR mice, but treatment with the steroid compound 17 alpha-ethynyl-19-nortestosterone (ANT) did mimic the combined effe(t of P and E. Since EMT could be induced by ANT in all ovariectomized adult GR mice within 3 weeks, this tumor-induction method was suitable for analysis of the gene responsible for palpable, pregnancy-dependent mammary tumors of this strain. Another argument for the usefulness of this test for genetic analysis was the fact that, though mouse mammary tumor virus (MuMTV) of the GR strain was introduced into BALB/c and tmas mice by foster-nursing, ANT treatment did not lead to EMT. First and second backcross analyses showed that one gene was responsible for EMT induction. There was a strong (orrelation between the presence of EMT and MuMTV antigens in the mammary glands and milk of several first backcross populations between GR and other strains such as C57BL, BALB/c, DBAf, and C3Hf. This suggested that the expression of MuMTV antigens was also controlled by the EMT gene. Two types of resistance phenomena were observed. Neither type could prevent EMT after hormone treatment; however, they could delay EMT development. One resistance factor for EMT induction was noticeable and dominant in reciprocal hybrids of the GR and DBAf strains, whereas another resistance factor was detected in the backcross population only [i.e., in the C57BL X (C57BL X Gr) ba(kcross] and not in hybrids; therefore, this factor was recessive. Until now, linkage experiments with 18 markers to locate the gene for EMT induction in the map of the mouse were unsuccessful.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 176379     DOI: 10.1093/jnci/56.1.27

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  6 in total

Review 1.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

2.  Pale cell carcinoma: ultrastructure of a hormone-dependent mammary tumor in GR mice.

Authors:  J M Strum
Journal:  Am J Pathol       Date:  1981-05       Impact factor: 4.307

3.  The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region.

Authors:  A C Cato; D Henderson; H Ponta
Journal:  EMBO J       Date:  1987-02       Impact factor: 11.598

4.  Identification of novel endogenous antisense transcripts by DNA microarray analysis targeting complementary strand of annotated genes.

Authors:  Koji Numata; Yuko Osada; Yuki Okada; Rintaro Saito; Noriko Hiraiwa; Hajime Nakaoka; Naoyuki Yamamoto; Kazufumi Watanabe; Kazue Okubo; Chihiro Kohama; Akio Kanai; Kuniya Abe; Hidenori Kiyosawa
Journal:  BMC Genomics       Date:  2009-08-22       Impact factor: 3.969

5.  Localization of a gene for expression of mouse mammary tumor virus antigens in the GR/Mtv-2- mouse strain.

Authors:  R Nusse; J de Moes; J Hilkens; R van Nie
Journal:  J Exp Med       Date:  1980-09-01       Impact factor: 14.307

6.  An exogenous mouse mammary tumor virus with properties of Mls-1a (Mtv-7).

Authors:  W Held; A N Shakhov; G Waanders; L Scarpellino; R Luethy; J P Kraehenbuhl; H R MacDonald; H Acha-Orbea
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.